Nanogen to Hold Conference Call on 2001 First Quarter Financial Results

Apr 18, 2001, 01:00 ET from Nanogen, Inc.

    SAN DIEGO, April 18 /PRNewswire/ -- Nanogen, Inc. (Nasdaq:   NGEN) will hold
 a conference call on Monday, April 30, at 4:30 p.m. Eastern Time to discuss
 2001 first quarter financial results.
     Howard Birndorf, Chairman and Chief Executive Officer, and Kieran
 Gallahue, President and Chief Financial Officer, will host the conference
 call.  Audio of the call will be available by live webcast and archived until
 May 7, 2001, through PR Newswire at
 http://www.videonewswire.com/NANOGEN/043001/.  Information about the
 conference call and webcast is also available at the Company's web site
 www.nanogen.com.
 
     Nanogen markets its NanoChip(TM) Molecular Biology Workstation system to
 scientists and genomics laboratories, setting new standards for SNP scoring.
 In addition, Nanogen is developing a series of electronics-based products to
 help researchers and clinical healthcare providers accelerate their practical
 understanding and use of genomic information.  The products introduced and
 under development are intended to provide quick and accurate analysis of DNA,
 RNA and proteins, and may eventually "bridge" the gap between the research and
 clinical settings.  The Nanogen system is intended for research use only and
 not for use in diagnostic procedures.  For additional information please visit
 Nanogen's web site at www.nanogen.com.
 
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including whether the
 Company's NanoChip(TM) system can be successfully commercialized, whether
 products under development can be successfully developed and commercialized,
 whether results reported by our customers or partners can be identically
 replicated, whether the Company's collaborations will continue to be funded,
 and other risks and uncertainties discussed under the caption "Factors That
 May Affect Results" and elsewhere in the Company's Form 10-K for the year
 ended December 31, 2000 filed with the Securities and Exchange Commission.
 These forward-looking statements speak only as of the date hereof.  The
 Company disclaims any intent or obligation to update these forward-looking
 statements.
 
 

SOURCE Nanogen, Inc.
    SAN DIEGO, April 18 /PRNewswire/ -- Nanogen, Inc. (Nasdaq:   NGEN) will hold
 a conference call on Monday, April 30, at 4:30 p.m. Eastern Time to discuss
 2001 first quarter financial results.
     Howard Birndorf, Chairman and Chief Executive Officer, and Kieran
 Gallahue, President and Chief Financial Officer, will host the conference
 call.  Audio of the call will be available by live webcast and archived until
 May 7, 2001, through PR Newswire at
 http://www.videonewswire.com/NANOGEN/043001/.  Information about the
 conference call and webcast is also available at the Company's web site
 www.nanogen.com.
 
     Nanogen markets its NanoChip(TM) Molecular Biology Workstation system to
 scientists and genomics laboratories, setting new standards for SNP scoring.
 In addition, Nanogen is developing a series of electronics-based products to
 help researchers and clinical healthcare providers accelerate their practical
 understanding and use of genomic information.  The products introduced and
 under development are intended to provide quick and accurate analysis of DNA,
 RNA and proteins, and may eventually "bridge" the gap between the research and
 clinical settings.  The Nanogen system is intended for research use only and
 not for use in diagnostic procedures.  For additional information please visit
 Nanogen's web site at www.nanogen.com.
 
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including whether the
 Company's NanoChip(TM) system can be successfully commercialized, whether
 products under development can be successfully developed and commercialized,
 whether results reported by our customers or partners can be identically
 replicated, whether the Company's collaborations will continue to be funded,
 and other risks and uncertainties discussed under the caption "Factors That
 May Affect Results" and elsewhere in the Company's Form 10-K for the year
 ended December 31, 2000 filed with the Securities and Exchange Commission.
 These forward-looking statements speak only as of the date hereof.  The
 Company disclaims any intent or obligation to update these forward-looking
 statements.
 
 SOURCE  Nanogen, Inc.